The association suspended Novo Nordisk in 2023 for not making clear its involvement in training on obesity drugs that the company offered to pharmacists on social media site LinkedIn, Reuters reported.
That year, Novo Nordisk became Europe's most valuable company, surpassing French luxury group LVMH, on the roaring success of its obesity drug Wegovy and diabetes drug Ozempic.
During the audit initiated as a result of the suspension, the PMCPA publicly reprimanded Novo Nordisk twice for further violations of the code, including for failing to properly record and describe payments it made to individuals including patients and journalists.
Novo Nordisk said it had considerably strengthened its compliance processes. "We firmly believe that we now have the right foundations and governance in place to be fully and effectively self-regulating."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.